Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Ex-Novartis Employee, Japan Unit Indicted over Diovan Data Manipulation
Tokyo prosecutors indicted a former employee of Novartis Pharma and the local arm of Swiss healthcare giant Novartis AG for an alleged violation of the Pharmaceutical Affairs Law (PAL) on July 1, local media reported. The special investigation squad of…
To read the full story
Related Article
- Court Finds Data Manipulation, but Not False Advertising: Diovan Case
March 17, 2017
- Novartis, Ex-Employee Found Not Guilty in Diovan Case
March 16, 2017
- Diovan Data Manipulation Case Closed, Ruling Due Out in March
December 16, 2016
- Prosecutors Seek 2.5 Years in Jail for Ex-Novartis Employee: Diovan Case
November 28, 2016
- Ex-Novartis Employee Pleads Not Guilty over Diovan Data Manipulation
December 17, 2015
REGULATORY
- Japan Begins Review of Domestic CGT Seeds with Limited Market Potential
June 30, 2026
- Govt Panel Urges 2027 Bill to Expand Secondary Use of Health Data
June 30, 2026
- Japan Panel OKs Carvykti’s Earlier Use in Multiple Myeloma
June 30, 2026
- Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
- MHLW Starts Technical Review of OTC-Like Drug Charge Exemptions
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…